Teva Pharmaceutical Industries Ltd Sample Clauses

Teva Pharmaceutical Industries Ltd and (ii) all of its respective past and present direct or indirect parents, subsidiaries, divisions, affiliates, joint ventures, predecessors, successors, assigns, including but not limited to Teva Pharmaceuticals USA, Inc., the Actavis Generic Entities, and Anda Inc.
Sample 1Sample 2Sample 3See All (6)
AutoNDA by SimpleDocs
Teva Pharmaceutical Industries Ltd and Teva Pharmaceuticals USA, Inc. hereby warrant and represent that, as of the date of the execution of this Agreement, it is not insolvent as such term is defined and interpreted under 11 U.S.C. §§101 et seq. (“Code”) including, without limitation, Code §§ 547 and 548.
Sample 1Sample 2
Teva Pharmaceutical Industries Ltd. (“Parent”) and the Borrower shall fail within one (1) business day following the date hereof to enter into an agreement and plan of merger in substantially the form of Exhibit A hereto whereby a wholly-owned subsidiary of Parent may commence an offer to purchase all of the outstanding shares of capital stock of the Borrower and, upon consummation of such offer, such subsidiary of Parent will merge with the Borrower resulting in the acquisition by Parent of the Borrower (the “Merger Agreement”) (capitalized terms used, but not defined in this Note, shall have the meanings given to such terms in the Merger Agreement);
Sample 1Sample 2
Teva Pharmaceutical Industries Ltd and Teva Pharmaceuticals USA, Inc. (collectively “Teva”); and (e) Xxxxxx Claims Administration LLC, as escrow agent (the “Escrow Agent”) is entered into on April 1, 2015, in connection with Teva’s Settlement Agreements with each of the Plaintiffs, dated April 1, 2015 (the “Settlement Agreements”). Capitalized terms not defined herein shall have the meanings specified in the Settlement Agreements.
Sample 1
Teva Pharmaceutical Industries Ltd. Tel: +000.0.0000000 Fax. +000.0.0000000. 0 Xxxxx Xxxxxx, Xxxxxx Xxxxx, Xxxxxx. 00000 [†] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION IVAX International GmbH Xxxxxxxxxxxx 0 0000 Xxxxxxxxxx Xxxxxxxxxxx Tel: +00 (0)00 000 0000 Fax: +00 (0)00 000 0000
Sample 1
Teva Pharmaceutical Industries Ltd. By: /s/ Xxxxx Xxxxx Name: Xxxxx Xxxxx Title: President, Teva Asia and Pacific By: /s/ Xxxxxx Xxxxxxx Name: Xxxxxx Xxxxxxx, Ph.D. Title: Corporate Vice President-Business Development Framework Agreement EXECUTION COPY Xxxxxxx Xxxxxxx as individual By: /s/ Xxxxxxx Xxxxxxx Name: Xxxxxxx Xxxxxxx EXECUTION COPY Xxxxxxx Xxxxxxx as individual By: /s/ Xxxxxxx Xxxxxxx Name: Xxxxxxx Xxxxxxx Framework Agreement EXECUTION COPY Xxxxxxx Xxxxxxx as individual By: /s/ Xxxxxxx Xxxxxxx Name: Xxxxxxx Xxxxxxx Framework Agreement Xxxxxxxx Xxxxxxx as individual By: /s/ Xxxxxxxx Xxxxxxx Name: Xxxxxxxx Xxxxxxx Framework Agreement EXECUTION COPY Marudai Industries Co., Ltd. By: /s/ Xxxxxxx Xxxxxxx Name: Xxxxxxx Xxxxxxx Title: Representative Director and President Framework Agreement Exhibits Exhibit A Subscription Agreement Exhibit B Disclosure Schedule Exhibit C Form SPA Exhibit D Guarantee Exhibit E Knowledge of TAIYO Exhibit F Other Family Shareholders Exhibit G Number of Shares and Apportioned Purchase Price concerning TAIYO, Family Shareholders and Other Family Shareholders Exhibit H Selected Other Selling Shareholders Exhibit I Framework of Bonus and Incentive Plan Exhibit J Details regarding Executive Officer System Framework Agreement FRAMEWORK AGREEMENT by and among TAIYO PHARMACEUTICAL INDUSTRY CO., LTD. ASAPH FARMACEUTISCHE ONDERNEMING B.V. XXXXXXX XXXXXXX XXXXXXX XXXXXXX XXXXXXX XXXXXXX XXXXXXXX XXXXXXX And MARUDAI INDUSTRIES CO., LTD. May 16, 2011 Framework Agreement
Sample 1

Related to Teva Pharmaceutical Industries Ltd

  • INDUSTRIAL PRODUCTS ARTICLE 3

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

  • Technology Research Analyst Job# 1810 General Characteristics Maintains a strong understanding of the enterprise’s IT systems and architectures. Assists in the analysis of the requirements for the enterprise and applying emerging technologies to support long-term business objectives. Responsible for researching, collecting, and disseminating information on emerging technologies and key learnings throughout the enterprise. Researches and recommends changes to foundation architecture. Supports research projects to identify and evaluate emerging technologies. Interfaces with users and staff to evaluate possible implementation of the new technology in the enterprise, consistent with the goal of improving existing systems and technologies and in meeting the needs of the business. Analyzes and researches process of deployment and assists in this process.

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

  • Diagnostic Services Procedures ordered by a recognized Provider because of specific symptoms to diagnose a specific condition or disease. Some examples include, but are not limited to:

  • New Technology When new or updated technology is introduced into a workplace, it will be the responsibility of the employer to provide appropriate and, if necessary, ongoing training to the employees directly affected. Such training will include any health and safety implications or information that will enable employees to operate the equipment without discomfort and will help maintain their general well-being.

  • MERCURY ADDED CONSUMER PRODUCTS Contractor agrees that it will not sell or distribute fever thermometers containing mercury or any products containing elemental mercury for any purpose under this Contract.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

Time is Money Join Law Insider Premium to draft better contracts faster.